ArticleAmerican journal of cancer research2015
Hispidulin prevents hypoxia-induced epithelial-mesenchymal transition in human colon carcinoma cells.
Article in American journal of cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Retraction Note: Physcion inhibits the metastatic potential of human colorectal cancer SW620 cells in vitro by suppressing the transcription factor SOX2.Acta pharmacologica Sinica · 2026Article
- Recent Update of Natural Compounds as HIF-1α Inhibitors in Colorectal Carcinoma.Drug design, development and therapy · 2025Review
- Hispidulin: a promising anticancer agent and mechanistic breakthrough for targeted cancer therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Antioxidant and Antiproliferation Activities of Lemon Verbena (Plants (Basel, Switzerland) · 2022Article
- Combined Anti-Adipogenic Effects of Hispidulin andBiomolecules · 2021Article
- Anti-Proliferative and Anti-Migratory Activities of Hispidulin on Human Melanoma A2058 Cells.Biomolecules · 2021Article
- Hispidulin exhibits potent anticancer activity in vitro and in vivo through activating ER stress in non‑small‑cell lung cancer cells.Oncology reports · 2020Article
- Hispidulin Inhibits Neuroinflammation in Lipopolysaccharide-Activated BV2 Microglia and Attenuates the Activation of Akt, NF-κB, and STAT3 Pathway.Neurotoxicity research · 2020Article
- Hispidulin Inhibits Mast Cell-Mediated Allergic Inflammation through Down-Regulation of Histamine Release and Inflammatory Cytokines.Molecules (Basel, Switzerland) · 2019Article
- The prognostic value of hypoxia-inducible factor-1α in advanced cancer survivors: a meta-analysis with trial sequential analysis.Therapeutic advances in medical oncology · 2019Article
- Targeting E-cadherin expression with small molecules for digestive cancer treatment.American journal of translational research · 2019Review
- Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3 signaling in colorectal cancer.Cancer science · 2018Article
- miR-542-3p inhibits colorectal cancer cell proliferation, migration and invasion by targeting OTUB1.American journal of cancer research · 2017Article
- Hispidulin suppresses tumor growth and metastasis in renal cell carcinoma by modulating ceramide-sphingosine 1-phosphate rheostat.American journal of cancer research · 2017Article
- Alpinumisoflavone suppresses tumour growth and metastasis of clear-cell renal cell carcinoma.American journal of cancer research · 2017Article
- miR-429 mediates tumor growth and metastasis in colorectal cancer.American journal of cancer research · 2017Article
- PTTG promotes invasion in human breast cancer cell line by upregulating EMMPRIN via FAK/Akt/mTOR signaling.American journal of cancer research · 2016Article
- Hispidulin induces mitochondrial apoptosis in acute myeloid leukemia cells by targeting extracellular matrix metalloproteinase inducer.American journal of translational research · 2016Article
- C4.4A as a biomarker of head and neck squamous cell carcinoma and correlated with epithelial mesenchymal transition.American journal of cancer research · 2015Review
Corrections and comments
- Correction · 2020-04-01Error in Image · Upgrade/Update of Prior Notice(s) ·
- Retraction · 2020-06-01Investigation by Third Party · Paper Mill · Plagiarism of/in Article · Upgrade/Update of Prior Notice(s) · · see also: https://scienceintegritydigest.com/2020/02/21/the-tadpole-paper-mill/; see also: https://pubpeer.com/publications/07DC50D5121A1E7B800432C74555D7;
- Erratum issued
- Retracted
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial-mesenchymal transition (EMT) is considered as the most important mechanism that underlies the initiation of cancer metastasis. Here we report that the naturally existing flavonoid, hispidulin is capable of preventing human colorectal cancer cells from hypoxia-induced EMT. The treatment of the cells with hispidulin reversed the EMT-related phenotype that has the morphological changes, down-regulation of E-cadherin, and hypoxia-induced cell migration and invasion. The effect was mediated at least in part by inhibiting the mRNA and protein expressions of HIF-1α via modulation of PTEN/PI3K/Akt pathway. In addition, we found that hispidulin-mediated prevention of the E-cadherin down-regulation and cell motility involved blockade of the hypoxia-induced up-regulation of Snail, Slug and Twist. Hispidulin was also effective in increasing expression of E-cadherin mRNA in HT29 colorectal cancer xenografts implanted in the nude mice. In summary, this study showed that hispidulin can prevent EMT induced by hypoxia, the environment that commonly exists in the center of a solid tumor. Given the low toxicity of hispidulin to the healthy tissues, our study suggests that hispidulin can serve as a safe therapeutic agent for suppressing cancer metastasis.
Indexed as
Identifiers
26045985PMC4449434W633924399What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.